Gilead Sciences, Inc. (GILD) to Issue Quarterly Dividend of $0.77 on June 27th

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Thursday, April 25th, Zacks reports. Stockholders of record on Friday, June 14th will be given a dividend of 0.77 per share by the biopharmaceutical company on Thursday, June 27th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.71%. The ex-dividend date of this dividend is Friday, June 14th.

Gilead Sciences has raised its dividend payment by an average of 3.3% annually over the last three years and has increased its dividend annually for the last 9 consecutive years. Gilead Sciences has a payout ratio of 42.1% indicating that its dividend is sufficiently covered by earnings. Analysts expect Gilead Sciences to earn $7.27 per share next year, which means the company should continue to be able to cover its $3.08 annual dividend with an expected future payout ratio of 42.4%.

Gilead Sciences Stock Up 0.2 %

Shares of GILD stock traded up $0.15 on Friday, hitting $65.42. The stock had a trading volume of 12,382,425 shares, compared to its average volume of 6,443,315. Gilead Sciences has a one year low of $64.63 and a one year high of $87.86. The business has a 50 day moving average price of $71.28 and a 200 day moving average price of $76.25. The company has a market cap of $81.45 billion, a PE ratio of 181.72, a P/E/G ratio of 1.17 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 23.08%. The business had revenue of $6.69 billion during the quarter, compared to analyst estimates of $6.36 billion. During the same quarter in the previous year, the business posted $1.37 EPS. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. Research analysts anticipate that Gilead Sciences will post 4.2 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Mizuho cut their target price on Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research report on Friday, April 19th. Cantor Fitzgerald decreased their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a research report on Wednesday, February 7th. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and cut their price target for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Finally, StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $83.87.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.